TRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report released on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Price Performance

Shares of NASDAQ TCON opened at $0.06 on Wednesday. TRACON Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $14.75. The firm has a 50-day simple moving average of $0.09 and a 200-day simple moving average of $0.63. The stock has a market capitalization of $197,780.00, a price-to-earnings ratio of 0.02 and a beta of 1.43.

TRACON Pharmaceuticals (NASDAQ:TCON) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter. The firm had revenue of $0.06 million during the quarter.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.